Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Tauns Laboratories, Inc. ( (JP:197A) ) is now available.
TAUNS Laboratories, Inc. has entered a strategic business alliance with ZACROS Corporation to enhance the development and manufacturing of components for next-generation Point of Care Testing (POCT) devices. This collaboration aims to leverage ZACROS’ biochip technology to innovate diagnostic products for the global market, potentially increasing the functionality and application range of TAUNS’ POCT devices. While the immediate financial impact is minimal, the partnership is expected to strengthen both companies’ positions in the medical diagnostics field by improving product efficiency and expanding market reach.
More about Tauns Laboratories, Inc.
TAUNS Laboratories, Inc., founded in 1987 in Shizuoka Prefecture, Japan, is a research and development-oriented company specializing in diagnostic technology. Known for its antigen test kits for respiratory infections, the company aims to expand into chronic disease diagnostics and next-generation Point of Care Testing (POCT) products. ZACROS Corporation, established in 1914, focuses on packaging materials and biotechnology products, leveraging its film lamination and coating technologies.
YTD Price Performance: -4.03%
Average Trading Volume: 1,011,198
Technical Sentiment Consensus Rating: Strong Sell
See more insights into 197A stock on TipRanks’ Stock Analysis page.